Colorcon Ventures Invests In Novome Biotechnologies, An Engineered Microbial Therapy Company
09/15/22, 12:03 PM
Location
san franciscoIndustry
therapeutics
biotechnology
health care
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Novome Biotechnologies, a clinical-stage company that develops engineered oral microbial therapies. The company's novel delivery platform controls the colonization of therapeutically engineered bacteria, enabling first-in-class treatment of chronic disorders such as inflammatory bowel disease and enteric hyperoxaluria.
Company Info
Location
san francisco, california, united states
Additional Info
Novome Biotechnologies is a biotechnology company developing engineered cellular therapies for the gut to treat chronic diseases. The Company has developed the first platform for the controlled colonization of the gut with engineered bacteria to deliver targeted therapeutic cargos and functions, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Based on pioneering technology developed at Stanford University, we bring together experts in the fields of synthetic biology and the microbiome to build novel cell-based therapies.